Xenon PharmaceuticalsXENE
About: Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Employees: 259
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
198% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $3.54M
8% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 71
0.85% more ownership
Funds ownership: 97.85% [Q1] → 98.7% (+0.85%) [Q2]
3% less funds holding
Funds holding: 217 [Q1] → 210 (-7) [Q2]
9% less capital invested
Capital invested by funds: $3.18B [Q1] → $2.9B (-$274M) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 10 [Q1] → 8 (-2) [Q2]
25% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 28
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
HC Wainwright & Co. Douglas Tsao 55% 1-year accuracy 80 / 146 met price target | 30%upside $53 | Buy Initiated | 1 Oct 2024 |
RBC Capital Brian Abrahams 41% 1-year accuracy 33 / 81 met price target | 35%upside $55 | Outperform Reiterated | 3 Sept 2024 |
Needham Serge Belanger 50% 1-year accuracy 57 / 115 met price target | 47%upside $60 | Buy Maintained | 12 Aug 2024 |
Cantor Fitzgerald Josh Schimmer 63% 1-year accuracy 47 / 75 met price target | 60%upside $65 | Overweight Reiterated | 9 Aug 2024 |
Wedbush Laura Chico 52% 1-year accuracy 38 / 73 met price target | 20%upside $49 | Outperform Maintained | 9 Aug 2024 |